BioPharma News

The biotechnology sector experienced a decline this week, with the SPDR S&P Biotech ETF (XBI) and the iShares Nasdaq Biotechnology ETF (IBB) decreasing by 4.35%

This week, biotech’s momentum strengthened going into March. The SPDR S&P Biotech ETF (XBI) grew by 7.56%, reaching $101.05. At the same time, the iShares

Over the past week, the biotechnology sector experienced a mild increase as exemplified by several prominent ETFs. Specifically, the SPDR S&P Biotech ETF (XBI) ascended

This week in the biotechnology industry, the SPDR S&P Biotech ETF (XBI) saw a modest rise, reaching $93.15 with a 2.16% increase. The iShares Nasdaq

This week, the biotechnology sector saw varied performances. The SPDR S&P Biotech ETF (XBI) remained somewhat static but eventually ended the week with a 4.43%

This week, the biotechnology sector experienced a bit of a hiccup, with the SPDR S&P Biotech ETF (XBI) trading sideways and closing the week down

This week in the biotechnology industry, the SPDR S&P Biotech ETF (XBI) witnessed a minimal change, closing at an increase of 0.63%. Along similar lines,

In this week’s industry newsletter, we’re thrilled to review the key outcomes of the recently concluded JP Morgan Healthcare Conference (JPM), an event that highlighted

Welcome officially to 2024! This week witnessed some interesting movements in the sector. The SPDR S&P ETF (XBI) saw a sideways movement, up by 0.55%,

As we welcome 2024, the biotech sector concluded 2023 with significant activity. The SPDR S&P Biotech ETF (XBI) closed the last week of the year